Trial Profile
Subretinal Macugen for Neovascular Age-Related Macular Degeneration (SUMANA)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegaptanib (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms SUMANA
- 24 Jun 2014 New trial record
- 20 Nov 2008